Non-commercial, multicenter, randomized, double-blind,
placebo-controlled phase 4 clinical trial.
The impact of intravenous treatment with iron carboxymaltose on mortality and morbidity due to cardiovascular causes, as well as on the quality of life of patients with myocardial infarction and concomitant iron deficiency.
We invite you to participate in the nationwide phase 4 clinical trial called INFERRCT, which aims to assess the impact of intravenous treatment with iron carboxymaltose compared to placebo on cardiovascular mortality, the risk of developing heart failure events during 12-month follow-up, and quality of life measured using the EQ-5D questionnaire during the first 8 months of observation in patients after myocardial infarction and iron deficiency.
In case of any technical problems, please contact:
email: [email protected]
im. Piastów Śląskich we Wrocławiu